Pleurodesis in chronic effusions : studies on inflammatory mediators, respiratory function, predictability of treatment outcome, drug efficiency and survival after treatment
Author: Ukale, Valiant
Date: 2004-10-08
Location: Thoraxklinikernas föreläsningssal N2:U1, Karolinska Universitetssjukhuset
Time: 9.00
Department: Institutionen för medicin / Department of Medicine
View/ Open:
Thesis (781.7Kb)
Abstract
Metastatic or primary (mesothelioma) malignancy of the pleura often
generates major pleura] effusion, giving respiratory distress and low
quality of life to the patients. Evacuation of fluid by thoracocentesis
gives only temporary relief, therefore pleurodesis is generally regarded
the best way to give palliation. The principle of pleurodesis is to cause
a severe inflammation with desquamation of the mesothelial cells,
resulting in a fibrosis that obliterates the pleural space. The aims of
this thesis were to study various aspects of chemical pleurodesis: the
inflammatory response in the pleura and the systemic inflammatory
reaction during such treatment and also to investigate if the reaction
had predictive value on pleurodesis outcome; the impact of pleurodesis on
respiratory function; to compare the efficacy and side effects of two
drugs used for pleurodesis; and the long-term survival after pleurodesis
in different malignancies.
It was found that the cytokine IL-1beta was present in the pleural fluid before and during chest tube drainage and increased after quinacrine instillation. However high concentrations of IL-10 values after instillation were related to the need for longer treatment duration. Successful pleurodesis leads to fibrous adhesions between the lung and costal pleura, which might restrict lung mobility. Ten patients without radiological signs of tumour infiltration and without visible signs of tumour growth in the pleural space at thoracoscopy were investigated after pleurodesis with static and dynamic spirometry, exercise testing with blood gas determination, and radiospirometry. The study showed that pleurodesis in malignant pleurisy has very limited influence on respiratory function.
Quinacrine has been used for pleurodesis with good results in our clinic for decades, and talc, which gradually during recent years become the most commonly used drug for this purpose world-wide. The comparative study between talc and quinacrine in 110 patients showed that both drugs were effective for pleurodesis. Fluid accumulation was stopped within six days in 96% of the talc group and 89% of the quinacrine group. All 89 prospective patients had verified malignant effusion. The markers investigated for the systemic inflammatory reaction were erythrocyte sedimentation rate, Creactive protein, and leukocyte count from venous blood samples, and fever reaction. Cessation of fluid accumulation was achieved in 82 patients (92%) and all had a prominent transitional elevation of the inflammatory parameters. The unsuccessful attempts (8%) caused negligible or very small elevations, but due to the small number, only the degree of fever after 8 and 48 hours showed a statistically significant difference. Pleurodesis causes a systemic inflammation and there is a tendency to a correlation between the success of pleurodesis and the degree of inflammation caused by the procedure.
Altogether 197 patients with malignant effusion were discharged from our clinic between January 1, 1991 to September 30, 1994 after a successful pleurodesis. The four most common primary tumours were lung, breast, lymphoma and ovarian malignancies. The overall median survival from pleurodesis was 135 days. Patients with breast cancer had the best prognosis (median survival 216 days). In lung cancer patients, this figure was 55 days and in lymphomas 168 days. The longer the time from diagnosis of primary turnour to effusion, the better the prognosis.
It was found that the cytokine IL-1beta was present in the pleural fluid before and during chest tube drainage and increased after quinacrine instillation. However high concentrations of IL-10 values after instillation were related to the need for longer treatment duration. Successful pleurodesis leads to fibrous adhesions between the lung and costal pleura, which might restrict lung mobility. Ten patients without radiological signs of tumour infiltration and without visible signs of tumour growth in the pleural space at thoracoscopy were investigated after pleurodesis with static and dynamic spirometry, exercise testing with blood gas determination, and radiospirometry. The study showed that pleurodesis in malignant pleurisy has very limited influence on respiratory function.
Quinacrine has been used for pleurodesis with good results in our clinic for decades, and talc, which gradually during recent years become the most commonly used drug for this purpose world-wide. The comparative study between talc and quinacrine in 110 patients showed that both drugs were effective for pleurodesis. Fluid accumulation was stopped within six days in 96% of the talc group and 89% of the quinacrine group. All 89 prospective patients had verified malignant effusion. The markers investigated for the systemic inflammatory reaction were erythrocyte sedimentation rate, Creactive protein, and leukocyte count from venous blood samples, and fever reaction. Cessation of fluid accumulation was achieved in 82 patients (92%) and all had a prominent transitional elevation of the inflammatory parameters. The unsuccessful attempts (8%) caused negligible or very small elevations, but due to the small number, only the degree of fever after 8 and 48 hours showed a statistically significant difference. Pleurodesis causes a systemic inflammation and there is a tendency to a correlation between the success of pleurodesis and the degree of inflammation caused by the procedure.
Altogether 197 patients with malignant effusion were discharged from our clinic between January 1, 1991 to September 30, 1994 after a successful pleurodesis. The four most common primary tumours were lung, breast, lymphoma and ovarian malignancies. The overall median survival from pleurodesis was 135 days. Patients with breast cancer had the best prognosis (median survival 216 days). In lung cancer patients, this figure was 55 days and in lymphomas 168 days. The longer the time from diagnosis of primary turnour to effusion, the better the prognosis.
List of papers:
I. Agrenius V, Ukale V, Widstrom O, Kallenius G, Svenson SB (1993). Quinacrine-induced pleural inflammation in malignant pleurisy: relation between drainage time of pleural fluid and local interleukin-1 beta levels. Respiration. 60(6): 366-72.
Pubmed
II. Ukale V, Bone D, Hillerdal G, Cederlund K, Widstrom O, Larsen F (1999). The impact of pleurodesis in malignant effusion on respiratory function. Respir Med. 93(12): 898-902.
Pubmed
III. Ukale V, Agrenius V, Hillerdal G, Mohlkert D, Widstrom O (2004). Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug. Lung Cancer. 43(3): 323-8.
Pubmed
IV. Ukale V, Agrenius V, Widstrom O, Alinaghizadeh H, Hillerdal G (2004). Inflammatory parameters after pleurodesis in recurrent malignant pleural effusions and their predictive value. Respiratory Medicine. [Accepted]
View record in Web of Science®
V. Ukale V, Alinaghizadeh H, Widstrom O, Hillerdal G (2004). Long-term survival of patients with malignant pleural effusions treated with chemical pleurodesis. [Submitted]
I. Agrenius V, Ukale V, Widstrom O, Kallenius G, Svenson SB (1993). Quinacrine-induced pleural inflammation in malignant pleurisy: relation between drainage time of pleural fluid and local interleukin-1 beta levels. Respiration. 60(6): 366-72.
Pubmed
II. Ukale V, Bone D, Hillerdal G, Cederlund K, Widstrom O, Larsen F (1999). The impact of pleurodesis in malignant effusion on respiratory function. Respir Med. 93(12): 898-902.
Pubmed
III. Ukale V, Agrenius V, Hillerdal G, Mohlkert D, Widstrom O (2004). Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug. Lung Cancer. 43(3): 323-8.
Pubmed
IV. Ukale V, Agrenius V, Widstrom O, Alinaghizadeh H, Hillerdal G (2004). Inflammatory parameters after pleurodesis in recurrent malignant pleural effusions and their predictive value. Respiratory Medicine. [Accepted]
View record in Web of Science®
V. Ukale V, Alinaghizadeh H, Widstrom O, Hillerdal G (2004). Long-term survival of patients with malignant pleural effusions treated with chemical pleurodesis. [Submitted]
Issue date: 2004-09-17
Rights:
Publication year: 2004
ISBN: 91-7140-031-1
Statistics
Total Visits
Views | |
---|---|
Pleurodesis ...(legacy) | 890 |
Pleurodesis ... | 145 |
Total Visits Per Month
September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | |
---|---|---|---|---|---|---|---|
Pleurodesis ... | 0 | 3 | 0 | 5 | 5 | 0 | 1 |
File Visits
Views | |
---|---|
thesis.pdf(legacy) | 700 |
thesis.pdf | 184 |
thesis.pdf.txt(legacy) | 2 |
Top country views
Views | |
---|---|
United States | 345 |
China | 69 |
Germany | 52 |
Sweden | 49 |
United Kingdom | 24 |
India | 21 |
South Korea | 19 |
Russia | 13 |
Nigeria | 12 |
Ireland | 10 |
Top cities views
Views | |
---|---|
Sunnyvale | 36 |
Beijing | 26 |
Romeo | 26 |
Seoul | 19 |
Kiez | 17 |
Lagos | 12 |
London | 11 |
Chisinau | 10 |
Stockholm | 9 |
Dublin | 8 |